Eli Lilly and Company (LLY)
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Healthcare sector poised for rebound in 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
Eli Lilly (LLY) closed the most recent trading day at $797.48, moving -0.3% from the previous trading session.
Lilly asks US government to pause drug price negotiation program, Bloomberg News reports
Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest prescription drugs, Bloomberg News reported on Monday, citing Lilly Chief Executive Dave Ricks.
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, are both looking to develop next-generation versions.
Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 bln
Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.
Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Andreessen Horowitz, Eli Lilly to launch $500 million venture fund
Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
LLY Falls Around 14% in 3 Months: How to Play the Stock
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Top pharmaceutical stocks to buy in 2025
Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.
